Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
General Internal Medicine
Would you ever omit adjuvant therapy for rectal cancer in patients who underwent primary resection (TME), without any neoadjuvant therapy?
What about T3N0 disease? Would you use a recurrence score to help inform decisions?
Related Questions
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Would you change treatment approach for rectal cancer with an associated intussusception?
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
Should GLP-1 agonists be held during chemotherapy?
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
In a patient with metastatic gastric cancer with high PDL-1 CPS score (10), at what point, if any, would you consider omitting chemotherapy and continuing immunotherapy alone based on CHECKMATE 649 if patient has a favorable or complete response?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?